By 2030, it is anticipated that the Japan infectious disease therapeutics market will reach a value of $10.88 Bn from $7.45 Bn in 2022, growing at a CAGR of 4.9% during 2022-2030. Infectious Disease Therapeutics in Japan is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Daiichi Sankyo and Takeda Pharmaceutical. The Infectious Disease Therapeutics market in Japan is segmented into different therapeutic areas and different diseases type. The major factors affecting the Japanese infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Japan.
By 2030, it is anticipated that the Japan infectious disease therapeutics market will reach a value of $10.88 Bn from $7.45 Bn in 2022, growing at a CAGR of 4.9% during 2022-2030.
Japan is a high-income developed island nation in East Asia. Japan has a well-developed healthcare system and a solid public health infrastructure, which has helped to keep infectious diseases under control. Antibiotic resistance is a major concern in Japan, and the government has taken several steps to address it, including promoting prudent antibiotic use and eliminating excessive prescribing. Japan has also had to deal with developing infectious disease epidemics, such as the COVID-19 pandemic.
In response to the pandemic, the Japanese government implemented strong border restrictions and quarantine measures, as well as encouraging immunisation and offering access to a variety of COVID-19 therapies. Japan has a comparatively high per capita healthcare spending, owing to the country's ageing population and the rising prevalence of chronic and infectious diseases. Japan's government spends 10.3% of its GDP on healthcare.
Market Growth Drivers Analysis
In Japan, there is a growing movement toward customised medicine, notably in infectious disease therapies. Biomarkers and genetic tests are used to personalise therapy for individual patients. Japan enjoys a privileged location in a rapidly developing region. Japan has advanced technology items and a diverse manufacturing sector. These aspects could boost Japan's infectious disease therapeutics market.
Market Restraints
The regulatory environment in Japan is known for its rigour and high standards, which might make it difficult for pharmaceutical companies to obtain approval and market their infectious disease medicines in the country. Japan is confronting a workforce decrease and low immigration contribution, which is increasing the share of precarious workers. These factors may deter new entrants into the Japanese infectious disease therapeutics market.
Key Players
October 2022: Takeda, Zedira, and Dr. Falk Pharma GmbH announced a collaboration and licencing agreement for the development of ZED1227/TAK-227, a Phase 2b experimental therapeutic for celiac disease. TAK-227 is a potentially first-in-class therapeutic aimed to block the immunological response to gluten in celiac disease, a serious autoimmune condition where the ingestion of gluten leads to inflammation and damage to the small intestine.
The Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour, and Welfare are principally in charge of the regulation and reimbursement of infectious disease medications in Japan (MHLW). Infectious illness medicines are frequently covered by Japan's national health insurance system, which covers more than 98 % of the population.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Japan infectious disease therapeutics market will reach a value of $10.88 Bn from $7.45 Bn in 2022, growing at a CAGR of 4.9% during 2022-2030.
In Japan, the regulation and reimbursement of infectious disease therapeutics are primarily overseen by the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW).
Infectious Disease Therapeutics in Japan is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Daiichi Sankyo and Takeda Pharmaceutical.